Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HC Wainwright & Co. Maintains Neutral on Kyverna Therapeutics, Lowers Price Target to $4

Author: Benzinga Newsdesk | April 03, 2025 07:28am

HC Wainwright & Co. analyst Mitchell Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and lowers the price target from $6 to $4.

Posted In: KYTX